Ferroptosis as a novel therapeutic target for cardiovascular disease.

Wu X, Li Y, Zhang S, Zhou X. · 2021

Read Ferroptosis as a novel therapeutic target for cardiovascular disease. by Wu X, Li Y, Zhang S, Zhou X. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7847684.txt.

Introduction

Wu and co-authors review ferroptosis as a fresh target in heart and vessel disease. How heart muscle cells die shapes many cardiac illnesses. Ferroptosis is a controlled form of cell death. Too much iron drives it, and toxic fat peroxides build up.

Iron, fat, amino acid, and glutathione handling all steer this death path. New evidence ties it to many diseases. In the heart, it plays roles in cardiomyopathy and heart attack. Reperfusion injury and heart failure involve it too. The authors set out how the process starts and how cells brake it. Blocking ferroptosis could protect heart tissue. They weigh the drug chances that follow.

Catalog record

CREATORWu X, Li Y, Zhang S, Zhou X.
YEAR2021
COLLECTIONPAPERS
FORMATTXT
FILE SIZE38 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7847684

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Ferroptosis as a novel therapeutic target for cardiovascular disease By Xiaoguang Wu, Yi Li, Shuchen Zhang, Xiang Zhou Published in: Theranostics DOI: 10.7150/thno.54113 ABSTRACT Abstract Cell death is an important component of the pathophysiology of cardiovascular disease. An understanding of how cardiomyocytes die, and why regeneration of cells in the heart is limited, is a critical area of study. Ferroptosis is a form of regulated cell death that is characterized by iron overload, leading to accumulation of lethal levels of lipid hydroperoxides. The metabolism of iron, lipids, amino acids and glutathione tightly controls the initiation and execution of ferroptosis. Emerging evidence shows that ferroptosis is closely associated with the occurrence and progression of various diseases. In recent years, ferroptosis has been found to play critical roles in cardiomyopathy, myocardial infarction, ischemia/reperfusion injury, and heart failure. This article reviews the mechanisms by which ferroptosis is initiated and controlled and discusses ferroptosis as a novel therapeutic target for various cardiovascular diseases. Keywords: ferroptosis, cardiomyopathy, myocardial infarction, ischemia/reperfusion injury, heart failure INTRODUCTION Over recent years, several forms of regulated cell death have been shown to be involved in the pathogenesis of cardiovascular diseases (CVDs) 1. Caspase-dependent apoptosis was the first mode of regulated cell death to be discovered 2, and in the ensuing decades, accounted for most of the research into cell death. Recently, autophagy has been identified as an evolutionarily conserved lysosomal-dependent pathway for degrading cytoplasmic proteins, macromolecules and organelles, which eventually leads to cell death 3. Ferroptosis is an iron-dependent form of regulated cell death that is characterized by the accumulation of lipid hydroperoxides to lethal levels, resulting in oxidative damage to cell membranes and is recognized to differ from apoptosis, necroptosis and autophagy in several aspects 4-6. Ferroptosis can be activated by iron overload or by inactivation of glutathione peroxidase 4 (GPX4), the major endogenous mechanism for preventing peroxidation 7-9, which converts potentially toxic lipid hydroperoxides into non-toxic lipid alcohols 10. In the latter case, ferroptosis can be suppressed by activating GPX4. Iron metabolism and activity of GPX4 are thus two major pathways that regulate sensitivity to ferroptosis. The molecular mechanisms underlying ferroptosis, especially which cell membranes are damaged to cause cell death, remain largely unknown. The morphology of cells that have undergone ferroptosis—which differs from other forms of cell death, such as apoptosis and necrosis—includes dense and compact mitochondria without cristae and loss of plasma membrane integrity. These characteristic morphological features are used as markers of ferroptotic cell death 4. Close links between ferroptosis and pathological processes, including degenerative and neoplastic diseases and ischemic injury, have recently been uncovered 11,12. Ferroptosis has been shown to be involved in drug-induced liver damage 13, acute kidney injury 14,15, neuronal death 16, and cancer cell death 17. Doxorubicin (DOX)-induced ferroptosis in cardiomyocytes causes distortion and enlargement of the myocardial mitochondria 18. Ferrostatins, liproxstatins and many other inhibitors of ferroptosis have been shown to protect the liver, kidney 15, brain 19 and heart 20 in mouse models of ischemic injury. These inhibitors can also reduce symptoms in animal models of degenerative brain disorders including Parkinson's disease 21,22 and Alzheimer's disease 23. The mechanism of ferroptosis was first described in cells of the central nervous system and shown to be distinct from that of apoptosis. Before introduction of the term 'ferroptosis', this type of cell death was termed 'oxidative glutamate toxicity' or 'oxytosis' 24. Neurological and neoplastic diseases have, for many years, been the focus of both research into the mechanism of ferroptosis and clinical applications. Recent studies have, however, uncovered the links between ferroptosis and CVDs. Ferroptosis is now known to play critical roles in cardiomyopathy, myocardial infarction (MI), ischemia/reperfusion injury (IRI), and heart failure (HF). Suppressing ferroptosis and thus preventing cardiac cell death is likely to become an effective therapeutic strategy for CVDs. MECHANISMS OF FERROPTOSIS The regulatory mechanisms of ferroptosis are complicated, involving a variety of signaling molecules and metabolic pathways (Figure 1). In this review, we summarize the important roles of iron, amino acid, and lipid metabolism in the pathogenesis of ferroptosis. [Figure: Schematic representation of the mechanism of ferroptosis. Ferroptosis is an iron-dependent form of regulated cell death mediated by lipid peroxidation of cellular membranes. Fe3+ imported through the transferrin receptor is converted to Fe2+ in endosomes and released from endosome by divalent metal transporter 1 (DMT1). Fenton reaction converts Fe2+ into Fe3+, which induces lipid peroxidation by activating lipoxygenases. Glutathione peroxidase 4 (GPX4) is the major endogenous mechanism to suppress lipid peroxidation. High extracellular concentrations of glutamate inhibit system Xc-, which imports cystine by exchanging intracellular glutamate for extracellular cystine. Cystine is subsequently converted to cysteine, which generates glutathione (GSH), a cofactor for GPX4. Erastin, glutamate, and sorafenib are inhibitors of system Xc-; RSL3, ML162 and FIN56 are inhibitors of GPX4.] Iron metabolism Iron is imported into the cell from the extracellular space through the transferrin receptor, and transferrin and the transferrin receptor are thus necessary for intracellular accumulation of lipid peroxides and ferroptosis 20. Iron imported into cells by transferrin is in the form of ferric ion (Fe3+), which is converted to ferrous ion (Fe2+) by ferric reductases in the endosome and transported from the endosome to the cytosol by divalent metal transporter 1. Shuttling of Fe2+ to Fe3+ via the Fenton reaction contributes to lipid peroxidation and the generation of reactive oxygen species (ROS) 25. Iron-sulfur clusters (Fe-S), which are formed from iron and sulfur, play a critical role in mitochondrial respiration 26, and autophagy has been shown to regulate sensitivity to ferroptosis by an effect on intracellular iron metabolism 27. Yu et al. 28 also demonstrated that the metal transporter Slc39a14 acts as a transporter for non-transferrin-bound iron (NTBI). Slc39a14 is not a major iron transporter under physiological conditions, but can function as a transporter of NTBI in the absence of transferrin. These findings suggest that Slc39a14 may induce ferroptosis by importing iron into the cell when transferrin is depleted. A number of regulatory proteins and receptors, together with other proteins, can regulate the initiation and execution of ferroptosis by altering lipid peroxidation and mitochondrial function through the control of iron metabolism. For example, heat shock protein beta-1 (HSPB1) and CDGSH iron sulfur domain 1 (CISD1) are both negative regulators of ferroptotic cancer cell death. Knockdown of HSPB1 enhances erastin-induced ferroptosis 29 and genetic inhibition of CISD1 enhances erastin-induced ferroptosis by increasing intra-mitochondrial lipid peroxidation 30. The master regulator, iron responsive element binding protein 2, together with the specific cargo receptor, nuclear receptor coactivator 4, which recognizes ferritin, can regulate sensitivity to ferroptosis by controlling iron metabolism 31. Selective autophagy of ferritin increases sensitivity to ferroptosis by regulating the availability of iron within cells 32. Amino acid metabolism GPX4 plays an indispensable role in the regulation of ferroptosis. Ferroptosis can be initiated both by direct inhibition of GPX4 and by inhibition of synthesis of glutathione (GSH), an essential cofactor for GPX4 function. Extracellular cystine is exchanged for intracellular glutamate in a 1:1 ratio by the plasma membrane cystine/glutamate antiporter, system Xc-, and then converted to cysteine, which is required to generate GSH. Suppression of cysteine uptake leads to accumulation of lipid peroxidation products 33. High extracellular concentrations of glutamate inhibit system Xc- and deplete intracellular

Read the complete text